DMRA
Galecto, Inc.
$18.14
Last traded — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.1B
52W Range2.01-38.325
Volume816,876
Avg Volume202,140
Beta1.57
Dividend—
Analyst Ratings
Company Info
CEOLori C. Firmani
Employees5
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-03-10
Websitegalecto.com
Boston, MA
US
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
Latest News
Recent Insider Trades
No insider trades found